AI-generated summary
The authors report a small randomized, double-blind, sham-controlled pilot study of an at-home near-infrared laser device added to standard care for severe diabetic foot ulcers in frail patients. Twenty patients were randomized, with 10 receiving active treatment and 10 receiving sham. The authors report greater wound size reduction and more wounds closing above 90% in the active group, and state that a larger trial is justified.
- Who or what was studied
- Frail adults aged about 63 years with type 2 insulin-dependent diabetes, neuropathy, peripheral artery disease, significant comorbidities and large osteomyelitis-associated diabetic foot ulcers
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The abstract describes a small pilot study with preliminary results that the authors say require a larger trial to confirm.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm
- Energy density (fluence)
- 8.8 J/cm2
- Power
- 250 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Sham, Laser, Primary outcome, Near-infrared, Pilot study, Neuropathy, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.